Novartis submitted an application to the FDA in 2Q 2025 for an intrathecal formulation (OAV101IT) of their one-time gene therapy onasemnogene abeparvovec (OAV101IT) for the treatment of spinal...

The event emphasizes additional measures for obesity therapy.

Prime Therapeutics researchers share more about award-winning real-world research

Editor-In-Chief: Maryam Tabatabai, PharmD Executive Editor: Anna Schreck Bird, PharmD Deputy Editors: Erik Hamel, PharmD; Olivia Pane, PharmD, CDCES A retrospective propensity score-matched cohort...

Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...

Generic Name Brand Name Brand Manufacturer Indication Approval Month* chikungunya vaccine, live Ixchiq® Valneva Austria Prevention of disease caused by Chikungunya virus November meningococcal...

Drug pipeline for October 2026 At Prime Therapeutics (Prime), we have positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen eye on...